NEW VIRAL AND NON-VIRAL PLATFORMS FOR T-CELL ENGINEERING

摘要

FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than ever for curative effects. However, many technical challenges in T cell gene delivery still remain in order for this therapy to become a standard of care practice. In this webinar, we will highlight the different viral and non-viral delivery approaches used in T cell engineering for cell and gene therapy applications including: · New solution for small-to-large scale serum-free, suspension lentiviral production - LV-MAX Lentiviral Production System · Platform development process using Design of Experiment (DOE) methodologies · High-throughput to large scale bioreactor protocols · Cost benefits of this system over current methods · Novel gene editing tools for primary T cells · New potent gene editing tools to increase knock-in and knock-out efficiency · Addressing non-viral delivery barriers through protocol optimization